RSV prevention is more important than ever, and pharmacy teams are on the front lines. In this episode, TRC Healthcare Associate Editor, Vickie Danaher, PharmD, reviews who should receive RSV vaccines, recent changes to age and risk-based recommendations, and how monoclonal antibodies protect infants and high-risk children. 

You’ll also hear practical tips on the best time to vaccinate patients, co-administration with other vaccines, product nuances, and safety considerations to help confidently guide patients through RSV prevention this season.

This is an excerpt from our October 2025 Pharmacy Essential Updates continuing education webinar series.

******

CE Information:

TRC Healthcare offers CE credit for this podcast for pharmacist subscribers at our platinum level or higher and pharmacy technician subscribers. Log in to your Pharmacist’s Letter or Pharmacy Technician’s Letter account and look for the title of this podcast in the list of available CE courses. None of the speakers have anything to disclose.

Claim Credit

******

Clinical Resources from Pharmacist’s Letter, Pharmacy Technician’s Letter, and Prescriber Insights: 

• Article: Stay Current on RSV Immunization Guidance
• Chart: RSV Vaccines
• Chart: Preventing RSV
• Chart: RSV Monoclonal Antibodies

Don’t miss out! Subscribe today to stay ahead with trusted insights and tools. 

Use code cc1025 at checkout for 10% off a new or upgraded subscription.

🎓 Are you a student? Great news—students can access a free version of Pharmacist’s Letter.

Send us a text

Email us: [email protected].

The content of this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment.

Find the show on YouTube by searching for ‘TRC Healthcare’ or clicking here.

Learn more about our product offerings at trchealthcare.com.

In this episode, Rachel Cole, PharmD, walks us through the evolving landscape of restless leg syndrome management, highlighting why dopamine agonists are no longer first-line therapy and what that means for clinical practice. 

You’ll learn about the importance of checking for iron deficiency, practical non-drug interventions, and alternative medications like gabapentin and pregabalin. 

Rachel shares actionable tips for educating patients, managing tricky cases, and staying up to date with the latest sleep medicine guidelines, so you can take confident steps forward in caring for patients with RLS.

This is an excerpt from our July 2025 Pharmacy Essential Updates continuing education webinar series.

******

CE Information:

TRC Healthcare offers CE credit for this podcast for pharmacist subscribers at our platinum level or higher and pharmacy technician subscribers. Log in to your Pharmacist’s Letter or Pharmacy Technician’s Letter account and look for the title of this podcast in the list of available CE courses. None of the speakers have anything to disclose.

Claim Credit

******

Clinical Resources from Pharmacist’s Letter, Pharmacy Technician’s Letter, and Prescriber Insights: 

• Article: Stay in Step With Treatments for Restless Legs Syndrome
• Chart: Oral Iron Comparison and Practical Considerations for Use

Don’t miss out! Subscribe today to stay ahead with trusted insights and tools. 

Use code cc1025 at checkout for 10% off a new or upgraded subscription.

🎓 Are you a student? Great news—students can access a free version of Pharmacist’s Letter.

Send us a text

Email us: [email protected].

The content of this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment.

Find the show on YouTube by searching for ‘TRC Healthcare’ or clicking here.

Learn more about our product offerings at trchealthcare.com.

In this episode, Rachel Cole, PharmD, explores the evolving landscape of medications for HIV pre-exposure prophylaxis (PrEP), spotlighting lenacapavir (Yeztugo)—a newly approved long-acting injectable option given just twice yearly. 

She walks through how it compares to oral therapies like Truvada and Descovy, plus other injectables such as cabotegravir. Rachel also offers practical guidance on identifying candidates for HIV PrEP, navigating lab requirements, and managing side effects. 

You’ll also hear strategies to help patients overcome cost barriers, improve adherence, and understand the importance of regular follow-up. 

Whether you’re supporting patients at the pharmacy counter or staying current on HIV prevention, this episode delivers timely insights for pharmacy teams and other healthcare professionals.

This is an excerpt from our September 2025 Pharmacy Essential Updates continuing education webinar series.

******

CE Information:

TRC Healthcare offers CE credit for this podcast for pharmacist subscribers at our platinum level or higher and pharmacy technician subscribers. Log in to your Pharmacist’s Letter or Pharmacy Technician’s Letter account and look for the title of this podcast in the list of available CE courses. None of the speakers have anything to disclose.

Claim Credit

******

Clinical Resources from Pharmacist’s Letter, Pharmacy Technician’s Letter, and Prescriber Insights:

• Article: Add Lenacapavir to Your List of PrEP Recommendations
• Checklist: HIV Pre-Exposure Prophylaxis (PrEP)
• New Drug Graphic: Lenacapavir (Yeztugo)
• Chart: Drug Interactions: Cytochrome P450 (CYP), P-glycoprotein, and More

Don’t miss out! Subscribe today to stay ahead. 

10% off a new or upgraded subscription with code cc1025 at checkout.

🎓 Student free version of Pharmacist’s Letter.

Send us a text

Email us: [email protected].

The content of this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment.

Find the show on YouTube by searching for ‘TRC Healthcare’ or clicking here.

Learn more about our product offerings at trchealthcare.com.

In this episode, TRC Healthcare editor, Vickie Danaher, PharmD, dives into the 2025/2026 flu vaccine season with a clear overview of what’s new and what remains consistent. From updated vaccine strain compositions and preferred products for older adults to thimerosal-free recommendations and egg allergy guidance, this episode equips you with the latest evidence-based insights.

She also tackles common patient questions, discusses coadministration with COVID-19 and RSV vaccines, and shares practical strategies to boost vaccine confidence and avoid administration errors.

Whether you're prepping for flu season or answering tough questions at the pharmacy counter, this episode has you covered.

This is an excerpt from our September 2025 Pharmacy Essential Updates continuing education webinar series.

******

CE Information:

TRC Healthcare offers CE credit for this podcast for pharmacist subscribers at our platinum level or higher and pharmacy technician subscribers. Log in to your Pharmacist’s Letter or Pharmacy Technician’s Letter account and look for the title of this podcast in the list of available CE courses. None of the speakers have anything to disclose.

Claim Credit

******

Clinical Resources from Pharmacist’s Letter, Pharmacy Technician’s Letter, and Prescriber Insights: 

• Article: Answer Questions About 2025-2026 Flu Vaccines
• Chart: Flu Vaccines for 2025-26 (United States)
• FAQ: Communicating About Flu Vaccination
• Article: Stay Current on RSV Immunization Guidance
• Article: Clarify Facts About COVID-19 Vaccines for 2025-2026

10% off a new or upgraded subscription with code cc1025 at checkout.

🎓 Student free version of Pharmacist’s Letter.

Send us a text

Email us: [email protected].

The content of this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment.

Find the show on YouTube by searching for ‘TRC Healthcare’ or clicking here.

Learn more about our product offerings at trchealthcare.com.

In this episode, TRC Healthcare editor, Vickie Danaher, PharmD, discusses how pharmacists and pharmacy technicians play a vital role in ensuring access to buprenorphine for opioid use disorder treatment. She’ll explore approaches to addressing dispensing barriers, inventory management strategies, and the importance of recognizing opioid use disorder as a chronic condition requiring appropriate long-term care. 

This is an excerpt from our March 2025 Pharmacy Essential Updates continuing education webinar series.

******

CE Information:

TRC Healthcare offers CE credit for this podcast for pharmacist subscribers at our platinum level or higher and pharmacy technician subscribers. Log in to your Pharmacist’s Letter or Pharmacy Technician’s Letter account and look for the title of this podcast in the list of available CE courses. None of the speakers have anything to disclose.

Claim Credit

******

The clinical resources mentioned during the podcast are part of a subscription to Pharmacist’s Letter, Pharmacy Technician’s Letter, and Prescriber Insights: 

• Article: Break Down Barriers to Dispensing Buprenorphine for OUD
• FAQ: Management of Opioid Use Disorder
• Graphic: Opioid Reversal Agents Quick Start Guide
• Course: Substance Use Disorders and Pain Management: MATE Act Training

Don’t miss out! Subscribe today to stay ahead with trusted insights and tools. 

Use code cc1025 at checkout for 10% off a new or upgraded subscription.

🎓 Are you a student? Great news—students can access a free version of Pharmacist’s Letter.

Send us a text

Email us: [email protected].

The content of this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment.

Find the show on YouTube by searching for ‘TRC Healthcare’ or clicking here.

Learn more about our product offerings at trchealthcare.com.

In this episode, TRC Healthcare editor, Rachel Cole, PharmD, evaluates 3 new migraine treatments: Atzumi, Brekiya, and Symbravo. She'll explain their dosing techniques and how they compare to existing therapies, while providing practical guidance on clinical considerations and cost-effective alternatives for acute migraine management.

This is an excerpt from our August 2025 Pharmacy Essential Updates continuing education webinar series.

******

CE Information:

TRC Healthcare offers CE credit for this podcast for pharmacist subscribers at our platinum level or higher and pharmacy technician subscribers. Log in to your Pharmacist’s Letter or Pharmacy Technician’s Letter account and look for the title of this podcast in the list of available CE courses. None of the speakers have anything to disclose.

Claim Credit

******

The clinical resources mentioned during the podcast are part of a subscription to Pharmacist’s Letter, Pharmacy Technician’s Letter, and Prescriber Insights: 

• Article: Stay Up to Date on “New” Migraine Meds
• Chart: Drugs for Acute Migraine
• Chart: Migraine Prophylaxis
• FAQ: Medication Overuse Headache

Don’t miss out! Subscribe today to stay ahead with trusted insights and tools. 

Use code cc1025 at checkout for 10% off a new or upgraded subscription.

🎓 Are you a student? Great news—students can access a free version of Pharmacist’s Letter.

Send us a text

Email us: [email protected].

The content of this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment.

Find the show on YouTube by searching for ‘TRC Healthcare’ or clicking here.

Learn more about our product offerings at trchealthcare.com.

In this episode, TRC Healthcare editor, Rachel Cole, PharmD, unpacks the updated recommendations for H. pylori management, spotlighting why bismuth quadruple therapy is now front and center and how to navigate antibiotic resistance and patient-specific factors. You’ll come away with actionable pearls on regimen selection, adherence strategies, and which drug interactions to watch for. 

This is an excerpt from our February 2025 Pharmacy Essential Updates continuing education webinar series.

The clinical resources mentioned during the podcast are part of a subscription to Pharmacist’s Letter, Pharmacy Technician’s Letter, and Prescriber Insights: 

• Article: Stay Current on H. pylori Treatment Guidance
• Chart: Helicobacter pylori: From Diagnosis to Eradication
• Graphic: Helicobacter pylori Treatment Summary

Don’t miss out! Subscribe today to stay ahead with trusted insights and tools. 

Use code cc1025 at checkout for 10% off a new subscription.

🎓 Are you a student? Great news—students can access a free version of Pharmacist’s Letter.

Send us a text

Email us: [email protected].

The content of this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment.

Find the show on YouTube by searching for ‘TRC Healthcare’ or clicking here.

Learn more about our product offerings at trchealthcare.com.

In this episode, TRC Healthcare editor, Vickie Danaher, PharmD, digs into Suzetrigine—brand name Journavx—the first non-opioid analgesic approved in over two decades. 

You’ll hear how it works, how it compares to hydrocodone/acetaminophen, and why it might be a game-changer for patients at risk of opioid misuse. We’ll also unpack limitations in the clinical trials, cost concerns, dosing nuances, and key drug interactions to watch for. Plus, we’ll share tips for counseling patients and navigating formulary decisions, especially if your site participates in the manufacturer’s pilot program. 

Don’t miss our quick skim graphic and comparison resource to help you make informed decisions.

This is an excerpt from our April 2025 Pharmacy Essential Updates continuing education webinar series.

The clinical resources mentioned during the podcast are part of a subscription to Pharmacist’s Letter, Pharmacy Technician’s Letter, and Prescriber Insights: 

• Article: Explain How Suzetrigine Stacks Up for Acute Pain
• Graphic: New Drug: Suzetrigine (Journavx)
• Resource: Analgesics for Acute Pain in Adults

Don’t miss out! Subscribe today to stay ahead with trusted insights and tools. 

Use code cc1025 at checkout for 10% off a new subscription.

🎓 Are you a student? Great news—students can access a free version of Pharmacist’s Letter.

Send us a text

Email us: [email protected].

The content of this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment.

Find the show on YouTube by searching for ‘TRC Healthcare’ or clicking here.

Learn more about our product offerings at trchealthcare.com.

In this episode, TRC Healthcare editor, Vickie Danaher, PharmD, discusses recently approved drug formulations that bring fresh options—and new challenges—to the pharmacy counter. 

From Arbli, the first ready-to-use losartan suspension, to Emrosi, a low-dose minocycline for rosacea, and Opipza, an oral film version of aripiprazole, we’ll walk through what makes each product unique and what pharmacy teams should watch for. We also cover HemiClor, a 12.5 mg chlorthalidone tablet that may help patients avoid splitting unscored tabs, Neffy, a needle-free epinephrine nasal spray now available in a pediatric strength, and wrap up with biosimilar updates on Merilog and Omlyclo. 

This is an excerpt from our June 2025 Pharmacy Essential Updates continuing education webinar series.

The clinical resources mentioned during the podcast are part of a subscription to Pharmacist’s Letter, Pharmacy Technician’s Letter, and Prescriber Insights: 

• Article: Watch for New Twists to Older Medications
• Chart: Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors
• Chart: Treatments for Rosacea
• Chart: Comparison of Commonly Used Diuretics
• Chart: Comparison of Atypical Antipsychotics
• Chart: Emergency Epinephrine Devices
• Chart: Facts About Biosimilars

Use code cc1025 at checkout for 10% off a new subscription.

Send us a text

Email us: [email protected].

The content of this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment.

Find the show on YouTube by searching for ‘TRC Healthcare’ or clicking here.

Learn more about our product offerings at trchealthcare.com.

In this episode, TRC Healthcare editor, Sara Klockars, PharmD, BCPS unpacks the newly approved use of tirzepatide (Zepbound) for obstructive sleep apnea (OSA)—a first-in-class pharmacologic option for a condition long managed with devices and lifestyle changes.

You’ll hear a concise review of sleep apnea pathophysiology, how tirzepatide works to reduce airway obstruction, and what the latest clinical trials reveal about its efficacy and safety. Plus,  you’ll get practical pharmacy-focused insights on side effect management, payer considerations, and how to avoid duplicate GLP-1 therapy. 

This is an excerpt from our April 2025 Pharmacy Essential Updates continuing education webinar series.

The clinical resources mentioned during the podcast are part of a subscription to Pharmacist’s Letter, Pharmacy Technician’s Letter, and Prescriber Insights: 

• Article: Watch for Tirzepatide for Sleep Apnea
• Chart: GLP-1 and GIP/GLP-1 Receptor Agonist Interactive Comparison Chart

Don’t miss out! Subscribe today to stay ahead with trusted insights and tools. 

Use code podcast1025 at checkout for 10% off a new subscription.

🎓 Are you a student? Great news—students can access a free version of Pharmacist’s Letter.

****

GLP-1 Essentials from TRC Healthcare – Now Available

Master the essentials of GLP-1 therapy with this focused GLP-1 agonists CE bundle. Get 4 hours of CE plus clinical tools to help you prescribe, titrate, switch therapies, and support patients confidently.

Courses include:

• GLP-1 Agonists: Understanding the Essentials (1.5 hours)
• GLP-1 Agonists: Supporting Success with Nutrition and Lifestyle Considerations (1 hour)
• GLP-1 Agonists: Optimizing Therapy Across Clinical Scenarios (1.5 hours)
• GLP-1 Agonists: Pipeline and Emerging Therapies (no CE credit; regular updates planned)

Now included with Pharmacist’s Letter Platinum and Diamond subscriptions, or available as a standalone CE experience.

****

Send us a text

Email us: [email protected].

The content of this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment.

Find the show on YouTube by searching for ‘TRC Healthcare’ or clicking here.

Learn more about our product offerings at trchealthcare.com.